3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Status
Completed
16
Withdrawn
2
Unknown
2
Terminated
2
Recruiting
2
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
30
Gynecologic
3
Genitourinary
3
Thoracic
2
Other
2
Dermatologic
2
Sarcoma
1
Other solid neoplasm
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
902
Lung Neoplasms
489
Small Cell Lung Carcinoma
140
Neoplasms
111
Melanoma
107
Neoplasm Metastasis
105
Breast Neoplasms
99
Colorectal Neoplasms
94
Ovarian Neoplasms
76
Carcinoma, Renal Cell
64
Pancreatic Neoplasms
62
Squamous Cell Carcinoma of Head and Neck
58
Mesothelioma
53
Stomach Neoplasms
51
Head and Neck Neoplasms
47
Adenocarcinoma of Lung
46
Triple Negative Breast Neoplasms
45
Esophageal Neoplasms
40
Colonic Neoplasms
40
Brain Neoplasms
40
Sarcoma
38
Mesothelioma, Malignant
38
Prostatic Neoplasms
37
Urinary Bladder Neoplasms
36
Recurrence
30
Carcinoma, Transitional Cell
28
Uterine Cervical Neoplasms
25
Endometrial Neoplasms
25
Carcinoma, Hepatocellular
21
Carcinoma, Squamous Cell
19
Interventions
pembrolizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
Oropharyngeal Neoplasms
×
Thoracic
×
Clear all
NCT04301011
2025-04-23
RAPTOR
Turnstone Biologics, Corp.
Phase 1
Terminated
27 enrolled
NCT03809624
2024-10-23
PDL1x41BB
Inhibrx Biosciences, Inc
Phase 1
Terminated
160 enrolled